Testosterone replacement therapy: Formulations, dosing, and what to expect

Testosterone replacement therapy replaces deficient testosterone with a goal of restoring levels to a physiologic or mid-normal range, as in the major testosterone trials, but it should only be used in men with persistent symptoms plus confirmed biochemical deficiency. The main TRT formulations are injections, gels, oral testosterone undecanoate, and less commonly buccal, nasal, and pellet systems. The practical choice comes down to level stability, reversibility, convenience, fertility plans, and route specific risk.

Key takeaways

• TRT is indicated for documented male hypogonadism, which means persistent symptoms plus biochemical evidence of deficiency, not for bodybuilding, anti aging, or “optimization” in men with normal testosterone.
• Veedma uses treatment thresholds of 350 ng/dL for total testosterone and 100 pg/mL for free testosterone when symptoms persist, and LH plus FSH must be checked before treatment selection.
• Short acting testosterone enanthate or cypionate at 250 mg every 2 to 3 weeks can produce wider peak and trough swings, while long acting testosterone undecanoate at 1,000 mg every 10 to 14 weeks provides steadier exposure.
• Transdermal gels at 1% to 2%, typically 50 to 100 mg daily, offer stable day to day levels and easy dose adjustment, but they carry a real secondary transfer risk to household contacts.
• For gel based TRT, serum testosterone is typically checked 2 to 4 hours after application to capture peak absorption and guide dose adjustment.
• Do not start TRT if hematocrit is 54% or higher, if fertility is an active goal, or if congestive heart failure is poorly controlled. Severe urinary symptoms, hematocrit of 48% to 50%, and a family history of venous thromboembolism require extra caution.

How TRT works and who it is for

TRT works by replacing testosterone that the body is not producing adequately, but it is appropriate only when persistent symptoms and biochemical deficiency are both present.^{[1] [2]}

Hypogonadism is the clinical syndrome of testosterone deficiency, not just a low lab number.

Exogenous testosterone raises circulating testosterone, improves androgen exposure in target tissues, and suppresses pituitary signaling to the testes while treatment is active.^[1]

Gonadotropins are the pituitary hormones LH and FSH that tell the testes to make testosterone and sperm.

According to the 2018 Endocrine Society guideline, and reinforced by randomized trial data, TRT benefits are documented in men who have symptoms plus consistently low testosterone, not in men with normal levels who want more muscle, better workouts, or a vague anti aging effect.^{[1] [3] [8]}

This distinction matters because the same drug that relieves real hypogonadism will also suppress LH, FSH, and spermatogenesis. In practical terms, TRT is a replacement strategy, not a “testosterone booster,” and it is contraindicated when a man has an active desire to have children.

Before any TRT option is chosen, the diagnosis has to be established correctly. At Veedma, that means morning blood testing from 07:00 to 11:00, direct free testosterone measurement by equilibrium dialysis with LC MS/MS, and mandatory LH plus FSH so the clinician can determine whether the man has primary hypogonadism, secondary hypogonadism, or a form that may respond better to stimulation therapy than to replacement. For the diagnostic framework, see the clinical definition of low testosterone, the complete low testosterone testing guide, and primary vs secondary hypogonadism.

That step should never be skipped. High LH with low testosterone points to primary testicular failure, where TRT is often necessary. Low or normal LH with low testosterone points to secondary or functional hypogonadism, where Enclomiphene may be the better first line choice because it preserves fertility and testicular function. Veedma’s model is to confirm the diagnosis first, then match treatment to the physiology, with over 40 biomarkers tracked twice per year or existing lab sets reviewed when men already have outside testing.

What TRT formulations are available

Modern TRT formulations include injections, transdermal gels, oral testosterone undecanoate, and less commonly buccal systems, intranasal gels, and subdermal pellets.^{[1] [2]}

Guidelines from the Endocrine Society and the European Association of Urology make the central point clearly. No single testosterone therapy type is universally best, because each route trades off convenience, pharmacokinetic stability, reversibility, and route specific adverse effects.

When men search for “TRT formulations” or “TRT options,” they often assume the decision is mainly about convenience. It is not. Formulation choice changes the pattern of hormone exposure, how easy it is to adjust the dose, how quickly a drug can be stopped, and how closely specific safety issues need to be followed.

This is also why testosterone therapy types are not interchangeable in practice, even when the same total weekly androgen exposure looks similar on paper. The route determines how the body sees the drug over time.

Testosterone injections vs gel and other TRT options

Testosterone injections usually create more peak to trough variation than gels, while gels provide the steadiest day to day exposure among the most commonly used short duration TRT options.^{[5] [6]}

Peak to trough variation means testosterone rises high after a dose and then falls before the next dose.

Short acting injections

Short acting injectable TRT usually means testosterone enanthate or cypionate. In the dosing schedule specified in the brief, these preparations are commonly given at 250 mg every 2 to 3 weeks. That schedule is effective, but many men notice the pharmacokinetic swing. Energy, libido, mood, and even perceived training capacity can feel better early in the interval and less stable later in the interval.

Direct head to head trial evidence between formulations is limited, but pharmacology, guideline consensus, and limited observational data suggest that short acting injections, especially when they produce larger serum peaks, may be more likely than gels to raise hematocrit and erythrocytosis risk.^{[5] [6]}

Erythrocytosis means an abnormal rise in red blood cell concentration.

Long acting testosterone undecanoate

Long acting testosterone undecanoate in castor oil, given at 1,000 mg every 10 to 14 weeks, is the injection formulation designed to smooth out those swings. Major guideline recommendations describe this preparation as a useful option when steadier replacement levels and less frequent dosing are priorities.^[2]

The tradeoff is reversibility. If hematocrit climbs, blood pressure becomes problematic, edema appears, or another adverse effect emerges, long acting testosterone undecanoate cannot simply be “turned off” the next day. It takes weeks to clear.

Gels

Gels are the most common answer to the question “testosterone injections vs gel” when the goal is stable replacement rather than convenience. Standard gel formulations are 1% to 2%, usually dosed at 50 to 100 mg per day. They deliver a more even daily exposure, are easy to titrate, and have a generally favorable safety profile when used properly.^{[2] [5]}

The drawback is transference. Testosterone left on the skin can transfer to a partner or child through close contact if the site is not fully dry or covered. For men living with children, or for men who know daily application adherence will be poor, this matters.

Oral, buccal, nasal, and pellet options

Oral testosterone undecanoate appeals to men who want a noninvasive option, but dosing and food instructions are product specific and approved products are taken twice daily with food or meals depending on the brand. All approved oral testosterone undecanoate products carry an FDA boxed warning about increased blood pressure, so blood pressure monitoring applies across the category.

Buccal systems, intranasal gels, and subdermal pellets are legitimate TRT options, but they are less commonly used. Intranasal products may suppress gonadotropins less and may carry a lower hematocrit burden than standard injections, but they require multiple daily doses and the evidence base is smaller than for gels and injectable therapy.

How testosterone replacement therapy dosing is set and monitored

Testosterone replacement therapy dosing is adjusted to keep testosterone in a physiologic or mid-normal replacement range, not to produce the largest possible peak.^{[3] [4]}

Physiologic means within the normal replacement range for adult men, rather than the supraphysiologic levels sought in performance drug use.

In the Testosterone Trials, investigators adjusted the gel dose to keep serum testosterone in the normal range for young men, effectively aiming for a physiologic or mid-normal range during the study.^{[3] [4]}

That approach is useful because it frames what good testosterone replacement therapy dosing is supposed to do. The goal is symptom relief with biologic replacement, not aggressive overshooting.

Timing matters for monitoring

For gels, serum testosterone is usually checked 2 to 4 hours after application to capture peak absorption. That timing matters. A level drawn too late can make an adequate dose look weak, and a level drawn at the right time gives a better basis for titration.

According to the Endocrine Society guideline, monitoring has to assess both effectiveness and safety. In real practice that means symptom review plus objective lab follow up, not a refill based on how the patient feels that week alone.^{[1] [6]}

What should be followed

Hematocrit is the percentage of blood volume made up by red blood cells.

At a minimum, testosterone therapy monitoring should track testosterone response, hematocrit, and route specific safety issues. If the man is 40 or older, PSA is typically included. Approved oral testosterone undecanoate products also require attention to blood pressure. At Veedma, monitoring is broader, with over 40 biomarkers assessed twice per year or existing outside labs reviewed and integrated into the treatment plan.

If testosterone is “in range” but symptoms have not moved, the next step is not automatically more testosterone. The clinician should reassess whether the diagnosis was correct, whether the chosen route is causing intolerable variability, and whether another condition is driving the symptoms.

How clinicians choose the right formulation

The right TRT formulation is the one that fits the patient’s risk profile, fertility goals, daily routine, and need for rapid withdrawal if adverse effects appear.^{[1] [2]}

There are no large definitive head to head outcome trials proving that one formulation is best for all men. According to international recommendations, route selection is therefore an individualized clinical decision, not a ranking contest among products.

When shorter acting options are smarter

Shorter acting formulations are usually the better starting point in higher risk men. Major guidelines generally favor gels or other shorter duration options over long acting depot therapy when the clinician wants the ability to stop treatment quickly if hematocrit rises, fluid retention becomes problematic, or another safety concern emerges.^{[1] [2]}

This is the practical downside of long acting testosterone undecanoate. It is convenient once the regimen is established, but it is a poor first choice when reversibility is especially important.

Matching the formulation to the man

Daily gels often fit men who want stable levels, easy dose adjustment, and the ability to stop quickly. Short acting injections fit men who do not mind dosing cycles and accept the possibility of wider hormonal swings. Long acting testosterone undecanoate fits men who value infrequent dosing and already have a clear safety plan. Oral testosterone undecanoate fits men who strongly prefer no needles and can reliably follow product specific twice daily dosing with food or meals while monitoring blood pressure.

Household context matters too. A man with frequent skin to skin contact with children may not be an ideal gel candidate. A man whose baseline hematocrit is already near the upper end of normal may be a poor candidate for a short acting injection strategy that pushes higher peaks.

Where Veedma fits

At Veedma, formulation selection starts with diagnosis and classification, not with a preferred product. The service offers a thorough workup with more than 40 biomarkers, or physician review of existing results from outside sources such as Function Health, followed by individualized treatment planning. Men with secondary or functional hypogonadism and LH below 8 mIU/mL are typically considered for Enclomiphene first, while Testosterone Cypionate or other TRT options are used when clinically indicated. Monitoring then continues with protocol adjustments rather than one fixed prescription.

Contraindications, risks, and what to expect after starting

TRT should not be started in men with active fertility goals, hematocrit of 54% or higher, untreated breast cancer, locally advanced or metastatic prostate cancer, or poorly controlled congestive heart failure.^{[1] [2]}

Absolute and relative contraindications

Lower urinary tract symptoms, often shortened to LUTS, are urinary symptoms such as urgency, frequency, nocturia, or weak stream.

IPSS is the International Prostate Symptom Score used to grade urinary symptom severity.

VTE means a blood clot in a vein, such as deep vein thrombosis or pulmonary embolism.

• Absolute contraindications include untreated breast cancer, locally advanced or metastatic prostate cancer, active desire to have children, hematocrit of 54% or higher, and uncontrolled or poorly controlled congestive heart failure.
• Relative contraindications include severe LUTS with an IPSS above 19, baseline hematocrit of 48% to 50%, and a family history of VTE.
• Every candidate should be screened before treatment starts. That screening is not paperwork. It determines whether TRT is appropriate at all, and if so, which route is safest.

Route specific risks and practical expectations

After starting TRT, what most men notice first is the delivery system itself. Short acting injections can feel effective but variable. Gels usually feel steadier but require daily discipline and attention to transfer precautions. Long acting testosterone undecanoate is convenient once established, but any adverse effect lasts longer because the drug cannot be cleared quickly. Approved oral testosterone undecanoate products avoid needles but tie the regimen to product specific food instructions and blood pressure follow up.

Direct comparative outcome evidence between formulations is limited, but observational data, broader safety literature, and the known peak to trough pharmacology of injectable therapy support the clinical impression that injections may be more likely than topical therapy to raise hematocrit, making blood count monitoring essential.^{[5] [6]}

The largest modern randomized safety study, TRAVERSE, followed 5,246 men for a mean of 33 months and found testosterone therapy noninferior to placebo for major cardiovascular events. That is reassuring, but it does not eliminate route specific adverse effects or the need for ongoing surveillance.^[7]

Most importantly, men should expect TRT to be a monitored medical therapy, not a one visit transaction. Hematocrit commonly rises within the first 3 to 12 months. Dose changes, route changes, or even discontinuation may be necessary depending on the response and safety profile. That is precisely why starting with the right diagnosis, the right TRT formulation, and the right monitoring plan matters more than choosing the most heavily marketed product.

Myth vs fact

Myth: More testosterone is always better.

Fact: TRT is replacement therapy, not a maximal dosing strategy. In the Testosterone Trials, dosing was adjusted into the normal range for young men, not to chase the highest possible number.^[4]

Myth: Testosterone injections are always superior to gel.

Fact: Testosterone injections vs gel is a tradeoff, not a hierarchy. Based on pharmacology, guideline consensus, and limited observational data, injections often create wider hormone fluctuations and may be more prone to erythrocytosis, while gels offer steadier day to day exposure but carry transference risk.^{[5] [6]}

Myth: TRT is an acceptable optimization tool for any tired man.

Fact: Evidence based guidelines restrict TRT to men with documented hypogonadism, meaning persistent symptoms plus biochemical deficiency. Men with normal testosterone should not receive TRT for anti aging, body composition “optimization,” or bodybuilding goals.^[1]

Bottom line

Testosterone replacement therapy comes in several formulations, but in real practice the key choices are short acting injections, long acting testosterone undecanoate, daily gels, and selected oral or niche delivery systems. The right regimen is the one that keeps testosterone in a physiologic range, matches the man’s risks and daily life, and can be monitored safely with special attention to fertility, hematocrit, and route specific adverse effects. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health: Male Hypogonadism. 2024. EAU Guidelines
3. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. The New England journal of medicine. 2016;374:611-24. PMID: 26886521
4. Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical trials. 2014;11:362-375. DOI: 10.1177/1740774514524032
5. Pastuszak AW, Gomez LP, Scovell JM, et al. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sexual medicine. 2015;3:165-73. PMID: 26468380
6. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2010;95:2560-75. PMID: 20525906
7. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England journal of medicine. 2023;389:107-117. PMID: 37326322
8. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology. 2018;200:423-432. PMID: 29601923